1 active not recruiting, 1 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Terminated 1 |
Follow Enpatoran: new trials by email Literature Review of Enpatoran trials Research Report on Enpatoran
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of M5049 in DM and PM Participants (NEPTUNIA) M5049 dose, Placebo - Dermatomyositis, Polymyositis | Phase 2 | Terminated | EMD Serono Research & Development Institute, Inc. | 20 | 2023-01-19 | 2026-09-09 |
| The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE) M5049 low dose, M5049 medium dose, M5049 high dose - Systemic Lupus Erythematosus | Phase 2 | Active not recruiting | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 381 | 2022-09-16 | 2026-10-15 |
Dermatomyositis (1) · Lupus Erythematosus, Cutaneous (1) · Lupus Erythematosus, Discoid (1) · Lupus Erythematosus, Systemic (1) · Myositis (1) · Polymyositis (1)
EMD Serono Research & Development Institute, Inc. (1) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (1)
Greece (2) · Poland (2) · Spain (2) · United States (2) · Argentina (1) · Australia (1) · Brazil (1) · Bulgaria (1) · Chile (1) · China (1) · Colombia (1) · Czechia (1) · Israel (1) · Italy (1) · Japan (1)